MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$627,303
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from standby equity pur...
Increase in accrued expenses and...
Net change in unrealized depreci...
Others
Negative Cash Flow Breakdown
Net loss
(increase) in inventory
Purchase of fixed assets
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-909,535
-942,720
-787,621
-1,509,566
Depreciation expense
7,102
6,222
7,602
5,991
Net change in unrealized depreciation (appreciation) and depreciation in gold bullions
74,015
-20,408
-33,689
30,968
Gain on sale of gold bullions
-
-
39,537
98,427
Stock issued for services
-
-
0
834,600
Imputed interest - related party
18,395
18,395
18,803
20,379
Fair value of options issued for services
10,157
10,157
10,157
4,197
Warrants issued/(cancelled) to consultants
-63,582
-206,864
-63,582
-97,842
(increase) decrease prepaid expenses
6,707
-4,176
4,176
-1,467
(increase) in inventory
59,835
45,240
0
22,183
Decrease in operating lease right-of-use, net
-19,921
-13,828
-13,567
-14,434
Increase in accrued expenses and other payables - related party
218,911
217,158
326,834
207,487
(decrease) increase in accounts payable
-15,481
14,977
-12,141
-34,264
Decrease in operating lease liabilities, current
-19,220
-13,127
-12,868
-14,784
Net cash used in operating activities
-598,695
-529,718
-449,487
-461,859
Proceeds from sale of investment in gold
-
-
73,445
222,754
Purchase of fixed assets
28,608
14,116
1,612
0
Net cash provided (used in) by investing activities
-28,608
-14,116
71,833
222,754
Proceeds from standby equity purchase agreement
1,127,959
1,644,588
677,198
1,069,335
Payment of debt offering costs
-
-
0
0
Principal payments on debt - related party
-
-
75,000
50,000
Net cash provided by financing activities
1,127,959
1,644,588
602,198
1,019,335
Net change in cash and cash equivalents
500,656
1,100,754
224,544
780,230
Cash and cash equivalents at beginning of period
2,890,990
1,790,236
1,565,692
673,264
Cash and cash equivalents at end of period
3,391,646
2,890,990
1,790,236
1,565,692
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from standby
equity purchase...
$1,127,959
(31.71%↑ Y/Y)
Net cash provided by
financing activities
$1,127,959
(33.27%↑ Y/Y)
Net change in cash
and cash...
$500,656
(346.23%↑ Y/Y)
Canceled cashflow
$627,303
Increase in accrued
expenses and other...
$218,911
(-47.05%↓ Y/Y)
Net change in
unrealized depreciation...
$74,015
(168.87%↑ Y/Y)
Warrants
issued/(cancelled) to consultants
-$63,582
(35.17%↑ Y/Y)
Decrease in operating
lease right-of-use,...
-$19,921
(27.98%↑ Y/Y)
Imputed interest -
related party
$18,395
(-54.12%↓ Y/Y)
Fair value of options
issued for services
$10,157
(21.00%↑ Y/Y)
Depreciation expense
$7,102
(-38.35%↓ Y/Y)
Net cash used in
operating activities
-$598,695
(31.78%↑ Y/Y)
Net cash provided
(used in) by investing...
-$28,608
(-119.94%↓ Y/Y)
Canceled cashflow
$412,083
Net loss
-$909,535
(31.42%↑ Y/Y)
Purchase of fixed assets
$28,608
(656.23%↑ Y/Y)
(increase) in inventory
$59,835
Decrease in operating
lease liabilities,...
-$19,220
(33.03%↑ Y/Y)
(decrease) increase in
accounts payable
-$15,481
(-144.85%↓ Y/Y)
(increase) decrease
prepaid expenses
$6,707
(149.65%↑ Y/Y)
Buy us a coffee
Kraig Biocraft Laboratories, Inc. (KBLB)
Kraig Biocraft Laboratories, Inc. (KBLB)